Severe Headache

ACP released new clinical guidance on outpatient treatment of acute episodic migraine with combination therapy in patients who are not pregnant or lactating in outpatient settings.

AUSTIN, Texas — More than 80% of those dealing with migraine or severe headaches reported cognitive impairment, with the most common being concentration difficulty, according to a presenter at the American Headache Society annual meeting.

Higher daily intake of dietary caffeine was associated with an increased prevalence of severe headache or migraine in adults, particularly women, according to researchers.

U.S. adults who reported a history of migraine or severe headache were 25% more likely to develop hypertension compared with those with no migraine history, with a higher risk for women vs. men, researchers reported.

Anthony DeWilde OD, FAAO, director of the tele-eye imaging program at VA Kansas City Health Care, discusses highlights from his presentation at Academy on the optometrist’s role in evaluating headaches in this Healio video.

Treating patients who have chronic migraine with both onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibody medications could reduce their monthly migraine days by an additional 5.6 days than if they had just received onabotulinumtoxinA alone, according to research presented at the American Headache Society Annual Meeting.

Fewer than one in five patients with migraine who have 4 headache days or more each month go through the steps needed to receive preventive treatment, according to results from the OVERCOME study presented at the American Headache Society’s Annual Meeting.